Amicus grabs Dimerix’s rare kidney disease drug for $30M upfront
Amicus Therapeutics has paid $30 million cash upfront to license US rights to a late-stage therapy for a rare kidney disease from the Australian biotech Dimerix. The deal provides for milestone...
View ArticleExclusive: AI biotech Stately Bio raises $12M for cell imaging
There are always trade-offs to make when studying cells. A biologist either kills the cell to scrutinize its insides or has to run more complex experiments, using tools like fluorescent tags to detect...
View ArticleLilly meets sales expectations, but Novo gains on PBM win
The weight loss race between Eli Lilly and Novo Nordisk is heating up. On Thursday morning, Eli Lilly posted $12.73 billion in revenue in the first quarter, a 45% jump from ...
View ArticleBiogen Q1 earnings: Leqembi sales improving slowly following lackluster launch
Biogen said sales of its Eisai-partnered Alzheimer’s drug Leqembi crept close to the $100 million mark in the first three months of the year, after the product fared worse than expected during its US...
View ArticleAfter hunt for alternatives, Kronos Bio selects Tang Capital's Concentra for...
Kronos Bio, the drug developer long led by Gilead veteran Norbert Bischofberger, is calling it quits. The biotech said Thursday it's selling to Tang Capital's shell company Concentra Biosciences for 57...
View ArticleArvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts
Plus, news about Repare Therapeutics, DCx Biotherapeutics, Bloomsbury Genetic Therapies and Zucara Therapeutics: Arvinas drops planned late-stage trials: The protein degrader specialist, along with its...
View ArticleFDA approves Satsuma's migraine nasal spray after rejection in 2024
The FDA approved a new nasal spray for migraines that was developed by Satsuma Pharmaceuticals. Previously called STS101, the company said Wednesday that the drug's brand name is Atzumi and is ...
View ArticleUS drugmakers seek clinical trials abroad as confidence in FDA wavers
When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began looking outside the US for a place to host a planned clinical trial ...
View ArticleCROs raise the alarm as clients delay R&D plans over funding, tariff worries
Contract research organizations Icon and Medpace have both reported high rates of canceled or delayed R&D projects on the back of the Trump administration's funding cuts and potential...
View ArticleFutureHouse debuts free AI agent for science platform
Open source doesn't necessarily mean easy access, and now the nonprofit FutureHouse is trying to bridge that gap for AI tools in science by launching a new platform. On Thursday, FutureHouse
View ArticleZocdoc launches an AI voice assistant
Zocdoc, the health tech company known for helping patients book doctor visits online, is launching an AI assistant to schedule appointments — over the phone. The AI agent, Zo by Zocdoc ...
View ArticleModerna’s vaccine revenue miss disappoints Wall Street
Moderna tried to assuage investors Thursday that enhanced scrutiny of its vaccines in the US wouldn’t hamper its progress. Ultimately, though, middling execution of the business may have proved to be...
View ArticleLilly CEO Ricks urges Trump to drop drug tariff plan
Eli Lilly CEO David Ricks continued his pushback against the Trump administration's plan to put tariffs on pharmaceutical products made outside the US, making some of the industry's most forceful...
View ArticleBristol Myers to close cell therapy site in Illinois
Bristol Myers Squibb is ending operations at a viral vector production site in the Chicago suburbs, a spokesperson for the company confirmed to Endpoints News. The move comes almost two years to the...
View ArticleExperts refute RFK Jr.'s claim that placebo-controlled trials for vaccines...
HHS Secretary Robert F. Kennedy Jr. claimed that moving forward, all new vaccines will need to be tested in placebo-controlled trials before they can win FDA approval, calling it "a radical departure...
View ArticleFDA adcomms to review data on long-term opioid use, overdoses
FDA advisors next week will discuss the risks of long-term opioid use during a joint-committee meeting that will examine two completed post-marketing studies the agency requested more than a decade...
View ArticleAmgen's obesity drug MariTide starts Phase 3, new program in Phase 1
While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play into Phase 3 studies. Amgen has emerged with one of the leading efforts in ...
View ArticleHHS launches $500M universal vaccine platform as RFK Jr. shakes up US vaccine...
The US Department of Health and Human Services rolled out a new $500 million initiative to develop universal vaccines for “pandemic-prone” viruses such as influenza and Covid-19. The effort announced...
View ArticleCytokinetics' stock drops after heart drug PDUFA pushed back due to lack of REMS
Cytokinetics said late Thursday that the PDUFA date for its heart disease therapy aficamten would be delayed by three months to Dec. 26. The lag would allow the FDA to review ...
View ArticleInvestors unveil plans for $1.3B cancer hub in London suburbs
Aviva Capital Partners and development company Socius are planning a new £1 billion ($1.3 billion) hub dedicated to cancer research in the town of Sutton, just outside central London. The cancer hub...
View Article